FATE - Fate Therapeutics EPS misses by $0.36 beats on revenue November, 05 2020 04:40 PM Fate Therapeutics Inc. Fate Therapeutics (FATE): Q3 GAAP EPS of -$0.68 misses by $0.36.Revenue of $7.56M (+211.1% Y/Y) beats by $0.07M.Press Release For further details see: Fate Therapeutics EPS misses by $0.36, beats on revenue